<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    11786451
   </pmid>
   <datecreated>
    <year>
     2002
    </year>
    <month>
     01
    </month>
    <day>
     11
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2002
    </year>
    <month>
     02
    </month>
    <day>
     07
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2009
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      0959-8138
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       324
      </volume>
      <issue>
       7329
      </issue>
      <pubdate>
       <year>
        2002
       </year>
       <month>
        Jan
       </month>
       <day>
        12
       </day>
      </pubdate>
     </journalissue>
     <title>
      BMJ (Clinical research ed.)
     </title>
     <isoabbreviation>
      BMJ
     </isoabbreviation>
    </journal>
    <articletitle>
     Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
    </articletitle>
    <pagination>
     <medlinepgn>
      71-86
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="OBJECTIVE" nlmcategory="OBJECTIVE">
      To determine the effects of antiplatelet therapy among patients at high risk of occlusive vascular events.
     </abstracttext>
     <abstracttext label="DESIGN" nlmcategory="METHODS">
      Collaborative meta-analyses (systematic overviews).
     </abstracttext>
     <abstracttext label="INCLUSION CRITERIA" nlmcategory="METHODS">
      Randomised trials of an antiplatelet regimen versus control or of one antiplatelet regimen versus another in high risk patients (with acute or previous vascular disease or some other predisposing condition) from which results were available before September 1997. Trials had to use a method of randomisation that precluded prior knowledge of the next treatment to be allocated and comparisons had to be unconfounded-that is, have study groups that differed only in terms of antiplatelet regimen.
     </abstracttext>
     <abstracttext label="STUDIES REVIEWED" nlmcategory="METHODS">
      287 studies involving 135 000 patients in comparisons of antiplatelet therapy versus control and 77 000 in comparisons of different antiplatelet regimens.
     </abstracttext>
     <abstracttext label="MAIN OUTCOME MEASURE" nlmcategory="METHODS">
      "Serious vascular event": non-fatal myocardial infarction, non-fatal stroke, or vascular death.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Overall, among these high risk patients, allocation to antiplatelet therapy reduced the combined outcome of any serious vascular event by about one quarter; non-fatal myocardial infarction was reduced by one third, non-fatal stroke by one quarter, and vascular mortality by one sixth (with no apparent adverse effect on other deaths). Absolute reductions in the risk of having a serious vascular event were 36 (SE 5) per 1000 treated for two years among patients with previous myocardial infarction; 38 (5) per 1000 patients treated for one month among patients with acute myocardial infarction; 36 (6) per 1000 treated for two years among those with previous stroke or transient ischaemic attack; 9 (3) per 1000 treated for three weeks among those with acute stroke; and 22 (3) per 1000 treated for two years among other high risk patients (with separately significant results for those with stable angina (P=0.0005), peripheral arterial disease (P=0.004), and atrial fibrillation (P=0.01)). In each of these high risk categories, the absolute benefits substantially outweighed the absolute risks of major extracranial bleeding. Aspirin was the most widely studied antiplatelet drug, with doses of 75-150 mg daily at least as effective as higher daily doses. The effects of doses lower than 75 mg daily were less certain. Clopidogrel reduced serious vascular events by 10% (4%) compared with aspirin, which was similar to the 12% (7%) reduction observed with its analogue ticlopidine. Addition of dipyridamole to aspirin produced no significant further reduction in vascular events compared with aspirin alone. Among patients at high risk of immediate coronary occlusion, short term addition of an intravenous glycoprotein IIb/IIIa antagonist to aspirin prevented a further 20 (4) vascular events per 1000 (P&lt;0.0001) but caused 23 major (but rarely fatal) extracranial bleeds per 1000.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Aspirin (or another oral antiplatelet drug) is protective in most types of patient at increased risk of occlusive vascular events, including those with an acute myocardial infarction or ischaemic stroke, unstable or stable angina, previous myocardial infarction, stroke or cerebral ischaemia, peripheral arterial disease, or atrial fibrillation. Low dose aspirin (75-150 mg daily) is an effective antiplatelet regimen for long term use, but in acute settings an initial loading dose of at least 150 mg aspirin may be required. Adding a second antiplatelet drug to aspirin may produce additional benefits in some clinical circumstances, but more research into this strategy is needed.
     </abstracttext>
    </abstract>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <collectivename>
       Antithrombotic Trialists' Collaboration
      </collectivename>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Meta-Analysis
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     England
    </country>
    <medlineta>
     BMJ
    </medlineta>
    <nlmuniqueid>
     8900488
    </nlmuniqueid>
    <issnlinking>
     0959-535X
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Platelet Aggregation Inhibitors
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      50-78-2
     </registrynumber>
     <nameofsubstance>
      Aspirin
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    AIM
   </citationsubset>
   <citationsubset>
    IM
   </citationsubset>
   <commentscorrectionslist>
    <commentscorrections reftype="Cites">
     <refsource>
      Stroke. 1996 Apr;27(4):588-92
     </refsource>
     <pmid version="1">
      8614912
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Thromb Haemost. 1996 Jul;76(1):94-8
     </refsource>
     <pmid version="1">
      8819259
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1996 Nov 16;348(9038):1329-39
     </refsource>
     <pmid version="1">
      8918275
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 Jan 18;349(9046):146-7
     </refsource>
     <pmid version="1">
      9111532
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 May 31;349(9065):1569-81
     </refsource>
     <pmid version="1">
      9174558
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1997 Jun 7;349(9066):1641-9
     </refsource>
     <pmid version="1">
      9186381
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1997 Aug 13;278(6):479-84
     </refsource>
     <pmid version="1">
      9256222
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Neurol Sci. 1997 Sep;151 Suppl:S1-77
     </refsource>
     <pmid version="1">
      9276859
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eur Heart J. 1998 Jan;19(1):40-54
     </refsource>
     <pmid version="1">
      9503175
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1998 Apr 7;97(13):1231-3
     </refsource>
     <pmid version="1">
      9570191
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1998 May 9;316(7142):1430-4
     </refsource>
     <pmid version="1">
      9572757
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1998 Oct 10;352(9135):1167-71
     </refsource>
     <pmid version="1">
      9777832
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1998 Dec 3;339(23):1665-71
     </refsource>
     <pmid version="1">
      9834303
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am J Cardiol. 2000 Mar 1;85(5):568-72
     </refsource>
     <pmid version="1">
      11078269
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Cardiovasc Risk. 2000 Dec;7(6):435-41
     </refsource>
     <pmid version="1">
      11189013
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 2001 Feb 3;357(9253):373-80
     </refsource>
     <pmid version="1">
      11211013
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 2001 Aug 16;345(7):494-502
     </refsource>
     <pmid version="1">
      11519503
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1992 Dec 12;340(8833):1421-5
     </refsource>
     <pmid version="1">
      1360557
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Stroke. 1992 Oct;23(10):1395-9
     </refsource>
     <pmid version="1">
      1412573
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1992 Sep 9;268(10):1292-300
     </refsource>
     <pmid version="1">
      1507375
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1991 Dec 5;325(23):1593-6
     </refsource>
     <pmid version="1">
      1669840
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Stroke. 1991 Aug;22(8):983-8
     </refsource>
     <pmid version="1">
      1866765
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      N Engl J Med. 1991 Oct 31;325(18):1261-6
     </refsource>
     <pmid version="1">
      1922220
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 1991 Jul 3;266(1):93-8
     </refsource>
     <pmid version="1">
      2046134
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eur Heart J. 1990 Apr;11(4):368-71
     </refsource>
     <pmid version="1">
      2139611
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1989 Nov 18;299(6710):1247-50
     </refsource>
     <pmid version="1">
      2513898
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Eur Heart J. 1999 May;20(10):725-41
     </refsource>
     <pmid version="1">
      10329064
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1999 Jun 26;353(9171):2179-84
     </refsource>
     <pmid version="1">
      10392981
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Drug Saf. 1999 Oct;21(4):325-35
     </refsource>
     <pmid version="1">
      10514023
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 2000 Jan 29;355(9201):330-1
     </refsource>
     <pmid version="1">
      10665546
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Cerebrovasc Dis. 2000 Mar-Apr;10(2):147-50
     </refsource>
     <pmid version="1">
      10686454
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 2000 Mar 14;101(10):1097-101
     </refsource>
     <pmid version="1">
      10715254
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Am Coll Cardiol. 2000 Apr;35(5):1103-15
     </refsource>
     <pmid version="1">
      10758948
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 2000 Apr 15;355(9212):1295-302
     </refsource>
     <pmid version="1">
      10776741
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Stroke. 2000 Jun;31(6):1240-9
     </refsource>
     <pmid version="1">
      10835439
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Stroke. 2000 Jul;31(7):1779-84
     </refsource>
     <pmid version="1">
      10884487
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 2000 Jul 8;356(9224):147-52
     </refsource>
     <pmid version="1">
      10963260
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      JAMA. 2000 Sep 27;284(12):1549-58
     </refsource>
     <pmid version="1">
      11000650
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1998 Dec 22-29;98(25):2829-35
     </refsource>
     <pmid version="1">
      9860783
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Am Heart J. 1997 Jun;133(6):703-12
     </refsource>
     <pmid version="1">
      9200399
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Br J Gen Pract. 1997 May;47(418):285-9
     </refsource>
     <pmid version="1">
      9219403
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Trends Pharmacol Sci. 1989 Nov;10(11):453-8
     </refsource>
     <pmid version="1">
      2514478
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1988 Jul 30;2(8605):245-7
     </refsource>
     <pmid version="1">
      2899236
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Blood. 1987 Jan;69(1):180-6
     </refsource>
     <pmid version="1">
      3790723
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1985 Dec;72(6):1177-84
     </refsource>
     <pmid version="1">
      3933848
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1995 Dec 9;346(8989):1509-14
     </refsource>
     <pmid version="1">
      7491044
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Arch Ophthalmol. 1995 Jan;113(1):52-5
     </refsource>
     <pmid version="1">
      7826294
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Lancet. 1993 Nov 20;342(8882):1255-62
     </refsource>
     <pmid version="1">
      7901582
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1994 Jan 22;308(6923):235-46
     </refsource>
     <pmid version="1">
      8054013
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Vasa. 1994;23(1):57-65
     </refsource>
     <pmid version="1">
      8154176
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1994 Jan 8;308(6921):81-106
     </refsource>
     <pmid version="1">
      8298418
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      BMJ. 1994 Jan 15;308(6922):159-68
     </refsource>
     <pmid version="1">
      8312766
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1993 Jan;87(1):162-4
     </refsource>
     <pmid version="1">
      8419003
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      J Neurol Neurosurg Psychiatry. 1993 Jan;56(1):17-25
     </refsource>
     <pmid version="1">
      8429318
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="Cites">
     <refsource>
      Circulation. 1993 May;87(5):1563-9
     </refsource>
     <pmid version="1">
      8491012
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2002 Jan 12;324(7329):103-5
     </refsource>
     <pmid version="1">
      11786458
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      ACP J Club. 2002 Jul-Aug;137(1):5
     </refsource>
     <pmid version="1">
      12093204
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="CommentIn">
     <refsource>
      BMJ. 2002 Jan 19;324(7330):167
     </refsource>
     <pmid version="1">
      11799038
     </pmid>
    </commentscorrections>
    <commentscorrections reftype="ErratumIn">
     <refsource>
      BMJ 2002 Jan 19;324(7330):141
     </refsource>
    </commentscorrections>
   </commentscorrectionslist>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Aspirin
     </descriptorname>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Cardiovascular Diseases
     </descriptorname>
     <qualifiername majortopicyn="N">
      mortality
     </qualifiername>
     <qualifiername majortopicyn="N">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Administration Schedule
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Drug Therapy, Combination
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Myocardial Infarction
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Platelet Aggregation Inhibitors
     </descriptorname>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Randomized Controlled Trials as Topic
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Risk Assessment
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Stroke
     </descriptorname>
     <qualifiername majortopicyn="Y">
      prevention &amp; control
     </qualifiername>
    </meshheading>
   </meshheadinglist>
   <otherid source="NLM">
    PMC64503
   </otherid>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2002
     </year>
     <month>
      1
     </month>
     <day>
      12
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2002
     </year>
     <month>
      2
     </month>
     <day>
      8
     </day>
     <hour>
      10
     </hour>
     <minute>
      1
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2002
     </year>
     <month>
      1
     </month>
     <day>
      12
     </day>
     <hour>
      10
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     11786451
    </articleid>
    <articleid idtype="pmc">
     PMC64503
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

